BioCurex Announces Receipt of Additional Proceeds From Public Offering

        Print
| Source: BioCurex, Inc.

RICHMOND, British Columbia, Jan. 29, 2010 (GLOBE NEWSWIRE) -- BioCurex, Inc. (OTCBB:BOCX) announced today that, on January 28, 2010, Paulson Investment Company Inc.,subsidiary of Paulson Capitol Corp, (Nasdaq:PLCC), the lead underwriter of its recently completed public offering, purchased an additional 92,280 units to cover over-allotments, from which the company received net proceeds of approximately $420,000. As a result, BioCurex sold in the offering an aggregate of 1,292,280 units, consisting of an aggregate of 90,459,600 shares of common stock and 90,459,600 redeemable warrants, and received aggregate net proceeds of approximately $5.7 million.  Approximately $1.2 million of the aggregate net proceeds will be used to reduce the outstanding principal on the company’s secured convertible notes to approximately $565,000.

Forward Looking Statement Disclaimer

This release contains a number of forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995.   Statements in this press release that are not statements of historical or current fact constitute “forward-looking statements.”  Such forward-looking statements involve known and unknown risks, uncertainties and other unknown factors that could cause the Company’s actual operating results to be materially different from any historical results or from any future results expresses or implied by such forward-looking statements.  In addition to statements that explicitly describe these risks and uncertainties, readers are urged to consider statements that contain terms such as “believes,” “belief,” “expects,” “expect,” “intends,” “intend,” “anticipate,” “anticipates,” “plans” and “plan,” to be uncertain and forward-looking.   The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the company’s filings with Securities and Exchange Commission. Since these statements involve risks and uncertainties and are subject to change at any time, the Company’s actual results could differ materially from expected results. The forward looking statements in this press release include statements regarding the intended use of proceeds from the offering.

Communications Act Disclaimer:

The company has not authorized the release of this information in any form that contravenes the Communication Act and will not be responsible for unsolicited massive distribution of this material by e-mail or facsimile by unauthorized parties.

About BioCurex

BioCurex is a development stage diagnostics company focusing on development and commercialization of products for the early detection, diagnosis, and monitoring of recurrence of cancer.  BioCurex has developed a blood test, Serum-RECAF™ that can detect the presence of cancer in humans and companion animals using a new cancer marker named RECAF™. The company’s web site is available at www.biocurex.com.

BioCurex
Ricardo Moro
(604) 207-9150